Author

J. J. Rodriguez-Sevilla

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

F. Ma· 2 shared G. Al-Atrash· 2 shared G. Garcia-Manero· 2 shared G. Montalban-Bravo· 2 shared H. Yang· 2 shared I. Ganan-Gomez· 2 shared N. Thongon· 2 shared S. Colla· 2 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Ma

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 28, 2023

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

V. Adema, I. Ganan-Gomez, F. Ma…·S. Colla

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

DOI 10.1101/2023.09.28.560018

humanclinical cohort / trial

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 7, 2023

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia

G. Montalban-Bravo, F. Ma, N. Thongon…·S. Colla

This study identifies MCL1 as a survival factor in RAS-mutated CMML, explaining resistance to BCL2 inhibitors and suggesting new therapeutic targets.

DOI 10.1101/2023.04.07.535928

humanscRNA-seq

𝕏 PostBluesky